Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors

BACKGROUND: Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging in recurr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Schäfer, Niklas, Gielen, Gerrit H., Rauschenbach, Laurèl, Kebir, Sied, Till, Andreas, Reinartz, Roman, Simon, Matthias, Niehusmann, Pitt, Kleinschnitz, Christoph, Herrlinger, Ulrich, Pietsch, Torsten, Scheffler, Björn, Glas, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425567/
https://ncbi.nlm.nih.gov/pubmed/30894200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-1846-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados